



Defense Health Agency, J-7, Continuing Education Program Office

DHA Clinical Pharmacy Course: Disease State Management

Enduring Material (home study), March 17 – June 6, 2025

Continuing Education (CE)/Continuing Medical Education (CME) Information

This CE/CME activity is accredited by the DHA, J-7, Continuing Education Program Office (CEPO). This activity provides continuing education for pharmacists and pharmacy technicians. A certificate of attendance is available for other attendees.

DHA Clinical Pharmacy Course: Disease State Management (14.00 clock hours)

Antibiotic Stewardship

Learning Objectives:

1. Describe antibiotic prescribing trends in the United States.
2. List the core elements of antimicrobial stewardship programs (ASPs).
3. Outline where to access antimicrobial stewardship resources.

Anticoagulation: Warfarin: Initiation, Monitoring, and Bridging; DOACs: Balancing Bleeds and Weight Extremes

Learning Objectives:

1. Decide which patients require warfarin over direct-acting oral anticoagulants (DOACs).
2. Determine outpatient management of venous thromboembolism (initiation, follow up, duration).
3. Describe appropriate transition to and from warfarin and its application before and after procedures.

Pharmacogenomics: The Foundation

Learning Objectives:

1. Explain the pharmacogenomics (PGx) field
2. Describe pharmacokinetic/pharmacodynamics principles and application to drug absorption, distribution, metabolism and elimination (ADME) involved in PGx

Contraceptive Management

Learning Objectives:

1. Describe the role of the provider in both preconception and contraception care.
2. Review contraceptives available.
3. Outline current guidelines for contraceptive management.

Pharmacogenomics in Mental Health

Learning Objectives:

1. Describe the evidence of pharmacogenomics in mental health (MH) prescribing.

Medication Management for Bariatric Surgery

Learning Objectives:

1. Summarize the types of bariatric surgery and candidates for bariatric surgery.
2. Explain the clinical pharmacists' role in bariatric medication management.
3. Evaluate medication management for certain chronic disease states such as hypertension, diabetes, and hyperlipidemia in patient pre/post-bariatric surgery.

Menopause and Female Sexual Dysfunction

Learning Objectives:

1. Review female reproductive life cycle.
2. Describe the role of the provider in treatment of genitourinary syndrome of menopause (GSM) and vulvovaginal atrophy (VVA).
3. Outline current guidelines for treatment of menopause symptoms.
4. Review pharmacotherapy treatments for female sexual dysfunction.

2024 Diabetes Updates

Learning Objectives:

1. Review diagnosis criteria for Diabetes.
2. Identify cardiorenal risk factors to determine appropriate medications for patients with T2DM.
3. Determine glycemic and HgA1c goals based on age and comorbid conditions.

Drug Therapy for Obesity Management

Learning Objectives:

1. Describe specific goals for older adults, children and adolescents.
2. Evaluate the current evidence supporting use of each class of anti-obesity medication.
3. Apply a weight loss management plan incorporating lifestyle intervention and pharmacotherapy for a patient who is a candidate for anti-obesity medication.

Infectious Disease Review for the Ambulatory Care Pharmacist

Learning Objectives:

1. Recall infectious disease states for which antimicrobial therapy is not commonly recommended
2. Summarize various antibiotic therapy for infectious diseases in the ambulatory care setting for adult patients

Continuous Glucose Monitors

Learning Objectives:

1. Compare and contrast continuous glucose monitoring technologies.
2. Identify appropriate candidates and optimize use of continuous glucose monitors (CGMs).

Faculty:

Janel Rossetto Pharm.D., M.S., B.C.N.S.P. Presenter has no financial or non-financial relationships to disclose.

Sarah Abel, Pharm.D., M.S.C.P., C.C.S.P. Presenter has no financial or non-financial relationships to disclose.

Rachael Coller, Pharm.D., B.C.P.S., B.C.P.P. Presenter has no financial or non-financial relationships to disclose.

Jennifer Kim, Pharm.D., B.C.A.C.P., B.C.A.D.M. Presenter has no financial or non-financial relationships to disclose.

Dr. Kim will discuss off-label uses for the following medications: bupropion (Actavis), naltrexone (Accord), topiramate (Par)

Kelly Campbell, Pharm.D., B.C.P.S. Presenter has no financial or non-financial relationships to disclose. Dr. Campbell will discuss off-label uses for individual components of Qsymia and Contrave for weight management

Jacqueline Merritt, Pharm.D. Presenter has no financial or non-financial relationships to disclose.

Azra Khan, Pharm.D., B.C.A.C.P., C.D.C.E.S. Presenter has no financial or non-financial relationships to disclose.

Kayla Scheps, Pharm.D., B.C.I.D.P., M.B.A. Presenter has no financial or non-financial relationships to disclose.

Megan Urias, Pharm.D., B.C.P.S. Presenter has no financial or non-financial relationships to disclose.

Mayce Vinson, Pharm.D., B.C.-A.D.M. Presenter has no financial or non-financial relationships to disclose.

Tabitha K. Oliver, Pharm.D., B.C.A.C.P., B.C.-A.D.M. Presenter has no financial or non-financial relationships to disclose.

Disclosures:

DHA J-7 staff, Planning Committee Members and content reviewers have no financial or non-financial interest to disclose. All faculty members have no financial or non-financial interest to disclose.

Pharmacists (ACPE)



UAN JA4008136-0000-25-030-H01-P

No valid paper/electronic statement of credit will be offered. DHA, J-7, CEPO is accredited by the American Council for Pharmacy Education (ACPE) to provide continuing education for Pharmacists. This knowledge based activity will provide a maximum of 14.00 contact hours of pharmacy continuing education credit. Participant CE records will be electronically communicated to CPE Monitor. There is no cost to participate in this activity.

Pharmacy Technicians (ACPE)



UAN JA4008136-0000-25-030-H01-T

No valid paper/electronic statement of credit will be offered. DHA, J-7, CEPO is accredited by the American Council for Pharmacy Education (ACPE) to provide continuing education for Pharmacy Technicians. This knowledge based activity will provide a maximum of 14.00 contact hours of pharmacy continuing education credit. Participant CE records will be electronically communicated to CPE Monitor. There is no cost to participate in this activity.

Other Professionals

All other health care professionals completing this CE/CME activity will be issued a Certificate of Attendance indicating participation and the number of hours of CE/CME credit. This may be used for submission to licensing boards for satisfaction of CE/CME requirements.

Commercial Support:

No commercial support was provided for this activity.

Participation Costs:

There is no cost to participate in this activity.

CE/CME Inquiries:

For all CE/CME related inquiries, please contact: dha.ncr.j7.mbx.continuing-education-office@health.mil

How to Obtain CE/CME Credit:

To receive CE/CME credit, you must complete the program posttest(s) and evaluation(s) before collecting your certificate(s). The posttests and evaluations will be available through 6 June 2025 at 2359 ET at the following URL:

www.dhaj7-cepo.com